Trial · NCT04152161
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on Positive QFT Test Results | Bacille Calmette Guerin (BCG) Group | 82 | Participants | ||
| Number of Participants With Sustained QuantiFERON®-TB Gold Plus Assay (QFT) Conversion From a Negative to Positive Test Based on Positive QFT Test Results | Placebo Group | 78 | Participants | ||
| Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 36-Months Follow-up or Discontinued Early | Bacille Calmette Guerin (BCG) Group | 74 | Participants | ||
| Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 36-Months Follow-up or Discontinued Early | Placebo Group | 73 | Participants | ||
| Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 48-Months Follow-up or Discontinued Early | Bacille Calmette Guerin (BCG) Group | 82 | Participants | ||
| Number of Participants With Sustained QFT Conversion From a Negative to Positive Test Based on Positive QFT Test Results at 48-Months Follow-up or Discontinued Early | Placebo Group | 78 | Participants | ||
| Number of Participants With Serious and Non-serious Solicited Adverse Events (AEs) Through 7 Days Post Vaccination | Bacille Calmette Guerin (BCG) Group | Any injection site symptom | 754 | Participants | |
| Number of Participants With Serious and Non-serious Solicited Adverse Events (AEs) Through 7 Days Post Vaccination | Placebo Group | Any injection site symptom | 381 | Participants | |
| Number of Participants With Serious and Non-serious Solicited Adverse Events (AEs) Through 7 Days Post Vaccination | Bacille Calmette Guerin (BCG) Group | Any general body symptom | 371 | Participants | |
| Number of Participants With Serious and Non-serious Solicited Adverse Events (AEs) Through 7 Days Post Vaccination | Placebo Group | Any general body symptom | 314 | Participants | |
| Number of Participants With Unsolicited AEs Through Day 28, as Well as Solicited AEs That Were Ongoing at Day 7 After Vaccination | Bacille Calmette Guerin (BCG) Group | 185 | Participants | ||
| Number of Participants With Unsolicited AEs Through Day 28, as Well as Solicited AEs That Were Ongoing at Day 7 After Vaccination | Placebo Group | 117 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Bacille Calmette Guerin (BCG) Group | 3 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Placebo Group | 3 | Participants | ||
| Number of Participants With AEs of Special Interest | Bacille Calmette Guerin (BCG) Group | Injection site abscess | 4 | Participants | |
| Number of Participants With AEs of Special Interest | Placebo Group | Injection site abscess | 0 | Participants | |
| Number of Participants With AEs of Special Interest | Bacille Calmette Guerin (BCG) Group | Suppurative lymphadenitis (Lymphadenitis bacterial) | 1 | Participants | |
| Number of Participants With AEs of Special Interest | Placebo Group | Suppurative lymphadenitis (Lymphadenitis bacterial) | 0 | Participants | |
| Number of Participants With AEs of Special Interest | Bacille Calmette Guerin (BCG) Group | Anaphylactic reaction | 0 | Participants | |
| Number of Participants With AEs of Special Interest | Placebo Group | Anaphylactic reaction | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04152161/results